drugset / Trial / NCT05068141
A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label, multicenter, phase II study to evaluate the efficacy and safety of SG001 in combination with Nab-paclitaxel in patients with advanced TNBC.
Timeline
- Start
- 2021-10-01
- Primary completion
- 2022-10-01
- Completion
- 2023-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enlonstobart | Monoclonal antibody | 240 mg | Intravenous |
| Subject | Paclitaxel | Small molecule | 100 mg/m2 | Intravenous |